Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, and in India, its prevalence is alarming. Studies estimate that between 9% and 22% of Indian women are affected — meaning nearly 1 in 5 of your female patients between 15 and 45 could walk into your OPD with undiagnosed or poorly managed PCOS. Yet search data shows that Indian doctors are actively looking for updated clinical answers: from the Rotterdam vs NIH criteria debate, to the right metformin dose, to what to do when first-line treatment fails. This guide covers the clinical essentials — diagnosis, workup, lifestyle and pharmacological management — with no fluff, just answers that matter at your OPD desk. Why PCOS Prevalence Is Higher in Indian Women Indian women are uniquely predisposed to PCOS due to a convergence of genetic, dietary, and metabolic factors. Higher rates of insulin resistance at lower BMI, a carbohydrate-dense diet, sedentary urban lifestyles, and a genetic predisposition toward hyperandrogenism all play a role. Critically, Indian women with PCOS are more likely to have the metabolic phenotype — insulin resistance, dyslipidaemia, and central obesity — compared to Western counterparts who more commonly present with the hyperandrogenic phenotype. This distinction matters because it shapes your workup and treatment plan. A lean Indian woman with irregular periods and acne can have severe metabolic PCOS — don't anchor on BMI when assessing severity. Diagnostic Criteria: Rotterdam vs NIH — What to Use in 2026 The Rotterdam 2003 criteria remain the most widely accepted and are endorsed by most Indian and international guidelines. Under Rotterdam, PCOS is diagnosed when 2 of the following 3 criteria are present: Oligo-ovulation or anovulation (cycles >35 days or <8 cycles/year) Clinical or biochemical hyperandrogenism (acne, hirsutism, elevated total/free testosterone) Polycystic ovarian morphology on ultrasound (≥20 follicles per ovary or ovarian volume >10 mL) Important: Always exclude other causes before diagnosing PCOS — specifically thyroid dysfunction, hyperprolactinaemia, congenital adrenal hyperplasia, and Cushing's syndrome. These mimics are common in Indian women and missing them is a serious clinical error. Recommended Workup for PCOS at Your OPD A focused, cost-effective workup is essential in Indian practice. Here is what most evidence-based guidelines recommend: Day 2–5 FSH, LH, prolactin, TSH, total testosterone (anti-Müllerian hormone if available) Fasting glucose and 75g OGTT — HbA1c alone misses early dysglycaemia in lean PCOS Fasting insulin and HOMA-IR (calculate: fasting glucose mmol/L × fasting insulin μIU/mL ÷ 22.5) Lipid profile — dyslipidaemia is present in up to 70% of Indian PCOS patients Pelvic ultrasound (transvaginal preferred if the patient consents; transabdominal acceptable) 17-OHP if atypical presentation (to rule out non-classical CAH) Treatment: What the Evidence Says in 2026 Treatment must be tailored to the patient's primary concern: menstrual irregularity, infertility, hyperandrogenism, or metabolic risk. There is no single protocol that fits all PCOS subtypes. 1. Lifestyle Modification — The Non-Negotiable First Step Even a 5–10% reduction in body weight in overweight women with PCOS restores ovulation in up to 55% of cases. Encourage a low-glycaemic index diet, regular aerobic exercise (150 min/week minimum), and sleep hygiene. For lean PCOS patients, focus on reducing refined carbohydrate load rather than calorie restriction. 2. Metformin — Still the Cornerstone of Metabolic PCOS Metformin 500 mg OD titrated to 1500–2000 mg/day is the standard first-line pharmacological therapy for PCOS with insulin resistance. It improves menstrual regularity, reduces androgen levels, and lowers the risk of progression to T2DM. Extended-release metformin (SR) is better tolerated in Indian patients who commonly report GI side effects. Inositol (myo-inositol 2g + D-chiro-inositol 50mg twice daily) is increasingly prescribed as an adjunct or alternative in patients intolerant to metformin, with emerging Indian data supporting its efficacy. 3. Combined Oral Contraceptives — For Hyperandrogenism & Cycle Regulation COCs with anti-androgenic progestins (drospirenone or cyproterone acetate) are the preferred choice for PCOS patients presenting with acne, hirsutism, or irregular cycles who do not desire fertility. Ethinyl estradiol 20–35 mcg combinations are standard. Always screen for thromboembolic risk before prescribing, and reassess every 6 months. 4. Ovulation Induction for Fertility Letrozole 2.5–5 mg on days 3–7 has replaced clomiphene citrate as the first-line ovulation induction agent in PCOS. Multiple meta-analyses confirm higher live birth rates with letrozole in PCOS, and this is now embedded in FOGSI, NICE, and AES guidelines. Clomiphene remains an option but should no longer be considered first choice. Refer to a reproductive endocrinologist if 3 cycles of letrozole fail. 5. GLP-1 Receptor Agonists in PCOS — The New Frontier Semaglutide and liraglutide are showing remarkable results in PCOS with obesity. In patients with BMI >27 and failed metformin response, GLP-1 agonists reduce insulin resistance, promote weight loss, and restore ovulation. FOGSI has recently opened guidance for off-label use in this indication. With semaglutide now more accessible in India (though still expensive), this is a conversation worth having with your metabolic PCOS patients. Long-Term Risks You Must Counsel Every PCOS Patient About PCOS is not just a gynaecological condition — it is a lifelong metabolic disorder. Indian women with PCOS have a 4–8x higher risk of developing Type 2 diabetes, a 2x higher risk of cardiovascular disease, and elevated risk of non-alcoholic fatty liver disease (now classified as MASLD). Endometrial hyperplasia and cancer risk are elevated due to chronic anovulation. Every PCOS patient should receive structured counselling about these long-term risks and be enrolled in annual metabolic monitoring — fasting glucose, lipid profile, blood pressure, and BMI. Frequently Asked Questions by Indian Doctors About PCOS Can a woman with regular cycles have PCOS? Yes. Under Rotterdam criteria, PCOS can be diagnosed with hyperandrogenism and polycystic morphology even without cycle irregularity. This 'normoandrogenic-ovulatory' subtype is less common but clinically significant for metabolic risk. Do not rule out PCOS solely on the basis of regular periods. How long should metformin be continued in PCOS? There is no universally agreed endpoint. Current guidance suggests continuing metformin as long as insulin resistance persists and the patient is tolerating it well. In prediabetic PCOS patients, long-term metformin is especially justified. Reassess annually. If the patient achieves normal weight with lifestyle changes and HOMA-IR normalises, a trial of tapering is reasonable. Is PCOS curable? PCOS is not curable in the traditional sense, but it is highly manageable. Many women see significant remission of symptoms with weight loss, particularly in the metabolic phenotype. Post-menopause, the hormonal component often resolves, but metabolic risk persists. Counsel patients that this is a lifelong condition requiring monitoring, not a death sentence. Does PCOS worsen with age? The androgenic and menstrual symptoms often improve with age as ovarian androgen production declines. However, the metabolic risk — insulin resistance, diabetes, cardiovascular disease — does not resolve and may worsen without proactive management. The window for metabolic intervention is in the reproductive years, not after menopause. What is the role of AMH in PCOS diagnosis? Anti-Müllerian hormone (AMH) is elevated in PCOS (typically 2–3x normal), reflecting the increased antral follicle count. While not currently a standalone diagnostic criterion, AMH >4.7 ng/mL is considered a strong PCOS marker and is increasingly included in proposed updated criteria. It is also a useful monitoring tool for treatment response — declining AMH levels indicate improving ovarian function. Is inositol effective in PCOS? Myo-inositol and D-chiro-inositol supplementation has Level 1 evidence for improving insulin sensitivity, menstrual regularity, and oocyte quality in PCOS. The physiological ratio of 40:1 (myo:D-chiro) is the most studied. It is safe, well tolerated, and increasingly prescribed as a first-line or adjunct therapy in India, particularly for patients who are metformin-intolerant or in the lean PCOS subtype. Should I screen all PCOS patients for depression? Yes. The prevalence of depression and anxiety is 3–4x higher in women with PCOS compared to the general population. Body image concerns, hirsutism, acne, infertility, and weight gain all contribute. Use the PHQ-9 or GAD-7 as a brief screen at diagnosis and annually. Refer to a mental health professional if scores indicate moderate-to-severe impairment. Treating PCOS without addressing its psychological burden leads to poorer outcomes. How DocTrust Helps You Manage PCOS Patients More Effectively Managing PCOS requires more than a single consultation — it demands ongoing metabolic monitoring, structured counselling, prescription tracking, and follow-up at key intervals. DocTrust's AI-powered clinic management platform helps you create structured care protocols for chronic conditions like PCOS. Automated WhatsApp reminders prompt patients for their annual metabolic screening, digital prescriptions keep treatment records accurate, and the OPD queue management system ensures you spend quality time with complex cases — not on paperwork. For clinics managing high volumes of female patients, DocTrust's reporting tools give you a population-level view of your PCOS cohort, so no patient falls through the cracks. Ready to streamline chronic disease management at your clinic? Get a free demo at www.doctrust.in and see how India's smartest clinics are transforming patient care.